Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Current Size And Growth Outlook For The Biologics CDMO Market?

The biologics Contract Development and Manufacturing Organization (CDMO) market has seen substantial growth in the past few years. From a size of $21.3 billion in 2024, it is projected to escalate to $24.15 billion in 2025, marking a compound annual growth rate (CAGR) of 13.4%. This significant growth during the historic period is due to factors like an increase in biologics development, cost efficiency and adaptability, an emphasis on core competences, regulatory compliance, quality assurance, and the globalization of pharmaceutical supply chains.

The biologics CDMO market is forecasted to experience a swift expansion in the forthcoming years, with its value expected to reach “$41.53 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.5%. The anticipated growth within this period can be credited to factors such as the escalating requirement for biologic therapies, the introduction of biosimilars and biobetters, investments in biomanufacturing setups, a shift towards delegating complex procedures, focus on the resilience of the supply chain and risk reduction, as well as regulatory harmonization and fast-tracked approvals. In this projection period, we are likely to witness an increased capacity for providing comprehensive solutions, absorption of single-use technologies, incorporation of continuous manufacturing processes, and the rise of specialized CDMOs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Market Forces Are Contributing To The Growth Of The Biologics CDMO Market?

An increase in the need for cell and gene therapy is forecasted to spur the expansion of the biologic CDMO industry. These novel therapeutic methods employ living cells or genetic elements to tackle root disease factors at a cellular or genetic level, offering potential management options for conditions that have traditionally been hard to handle or untreatable with customary pharmaceuticals. The escalating need for these therapies stems from their capacity to potentially yield novel treatments for diseases by handling root cellular or genetic causes. Biologic CDMOs bring expertise to the table in managing living cells, viral vectors, and genetic elements, ensuring they are safely and efficiently incorporated in the production of cell and gene therapies, all while aiding biopharmaceutical businesses in understanding regulatory necessities and technical hurdles, thus ensuring a smooth transition from research to clinical implementation. For instance, The American Society of Gene & Cell Therapy (ASGCT), a primary professional association based in the US, reported a 7% increase in the gene, cell, and RNA therapy pipeline in 2022, totaling 3,726 therapies under development. Of these, 55% are dedicated to gene therapies, with 22% assigned to non-genetically modified cell therapies and the remaining 23% focusing on RNA therapies. Therefore, this growing interest in cell and gene therapy is propelling the expansion of the biologic CDMO market.

What Are The Key Segment Trends Observed In The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Which Disruptive Trends Are Driving Change Across The Biologics CDMO Market?

Leading firms in the biologics CDMO industry are creating advanced technological solutions such as innovative cell lines to advance the efficiency and capabilities of biopharmaceutical development and manufacturing. This new technology generates therapeutic antibodies with improved potency, which aim to tackle the hurdles in immunotherapy research and development. A case in point is the launching of GS Effex cell lines by Lonza Group, a Swiss manufacturing company focused on the pharmaceutical and biotechnology industries, in November 2023. These cell lines are crafted to manufacture antibodies that are completely devoid of fucose, a sugar molecule, thus displaying heightened potency without any compromise on other performance qualities. This addresses the immunotherapy research and development issues associated with the demand for potent antibody therapeutics. The GS Effex cell lines are stable, scalable, and efficient which cater to the needs of therapeutic development right from discovery-stage research to commercial manufacturing.

Who Are The Major Stakeholders Operating In The Biologics CDMO Market?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

What Regional Factors Are Accelerating Growth In The Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model